Viatris (VTRS) Interest Expenses (2019 - 2026)
Viatris' (VTRS) quarterly Interest Expenses came in at $1.2 billion in Q1 2026, down 2.19% year-on-year from $1.2 billion in Q1 2025, and up 908.36% quarter-over-quarter from $119.6 million in Q4 2025.
Viatris (VTRS) Interest Expenses (2019 - 2026) Analysis & Trends
Viatris' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- On a quarterly basis, Interest Expenses fell 2.19% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 2.19% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 16.75% from the prior year.
- Interest Expenses grew to $1.2 billion in Q1 2026 per VTRS's latest filing, from $119.6 million in the prior quarter.
- Across five years, Interest Expenses topped out at $2.1 billion in Q1 2022 and bottomed at $119.6 million in Q3 2025.
- The 5-year median for Interest Expenses is $147.1 million (2022), against an average of $874.5 million.
- Across the five-year window, Interest Expenses sank 93.15% in 2023 and soared 747.05% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $147.1 million in 2022, then retreated by 4.21% to $140.9 million in 2023, then dropped by 14.69% to $120.2 million in 2024, then retreated by 0.5% to $119.6 million in 2025, then jumped by 908.36% to $1.2 billion in 2026.
- Per Business Quant, the three latest VTRS Interest Expenses figures stand at $1.2 billion (Q1 2026), $119.6 million (Q4 2025), and $119.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 258.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.21 Bn |
| Mar 31, 2026 | 1.21 Bn |
| Dec 31, 2025 | 119.60 Mn |
| Dec 31, 2025 | 119.60 Mn |
| Sep 30, 2025 | 119.60 Mn |
| Sep 30, 2025 | 119.60 Mn |
| Jun 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.24 Bn |
| Mar 31, 2025 | 1.23 Bn |
| Mar 31, 2025 | 1.23 Bn |
| Dec 31, 2024 | 120.20 Mn |
| Dec 31, 2024 | 120.20 Mn |
| Sep 30, 2024 | 145.60 Mn |
| Sep 30, 2024 | 145.60 Mn |
| Jun 30, 2024 | 145.80 Mn |
| Jun 30, 2024 | 145.80 Mn |
| Mar 31, 2024 | 1.77 Bn |
| Mar 31, 2024 | 1.77 Bn |
| Dec 31, 2023 | 140.90 Mn |
| Dec 31, 2023 | 140.90 Mn |